Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects

• Published in: Hepatology (Baltimore, Md.) Vol. 62; no. 3; pp. 684 - 693
• Main Authors: Wong, Grace Lai‐Hung, Tse, Yee‐Kit, Wong, Vincent Wai‐Sun, Yip, Terry Cheuk‐Fung, Tsoi, Kelvin Kam‐Fai, Chan, Henry Lik‐Yuen
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc 01.09.2015
• Subjects: Acute Kidney Injury - chemically induced; Acute Kidney Injury - epidemiology; Administration, Oral; Adult; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Cohort Studies; Confidence intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Fractures; Fractures, Bone - chemically induced; Fractures, Bone - epidemiology; Health risk assessment; Hepatitis; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic - diagnosis; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - mortality; Hepatology; Hong Kong; Humans; Male; Middle Aged; Nucleosides - administration & dosage; Nucleosides - adverse effects; Nucleotides - administration & dosage; Nucleotides - adverse effects; Retrospective Studies; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome; Hong Kong

Widespread and long‐term use of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a real‐life setting. We aimed to determine the risks of renal and bone side effects in patients receiving or who have received NAs as CHB treatment. A territory‐wide cohort...